Bernstein raised the firm’s price target on Tilray (TLRY) to $10 from $1 and keeps a Market Perform rating on the shares after President Trump signed an Executive Order related to cannabis. The firm says Tilray is positioned benefit from the regulatory changes. The company yesterday announced the formation of Tilray Medical USA, with the aim of drawing on its global experience in medical cannabis operations to win in the U.S., the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLRY:
- Alliance Global says mandate for cannabis banking could come at another time
- CGC, TLRY, CRON: Cannabis Stocks Soar as Trump Reclassifies the Drug
- Trump increasing medical marijuana and cannabidiol research
- Tilray accelerates U.S. medical cannabis expansion after federal rescheduling
- President Trump says marijuana order ‘not legalization’